Law360, New York (October 29, 2008, 12:00 AM ET) -- For the third time since reintroducing the treatment to the market, Biogen Idec Inc. has said that a multiple sclerosis patient treated with its drug Tysabri has developed a rare but potentially fatal brain disease.
In a filing with the U.S. Securities and Exchange Commission on Wednesday, Biogen said it had notified agencies of a confirmed case of progressive multifocal leukoencephalopathy in a person using the drug to treat multiple sclerosis. The company said the patient received 14 infusions of Tysabri monotherapy and is under the...
Biogen Says Another Falls Ill After Taking MS Drug
To view the full article, take a free trial now.
